ReST THERAPEUTICS

ReST Therapeutics is developing transformative therapies for patients with significant unmet needs in Psychiatry and Neurodegeneration. Our lead program, RST-01, will disrupt the existing PTSD treatment paradigm, focusing on early intervention in the aftermath of a traumatic event and a patient-centric clinical strategy. RST-01 targets specific NMDA receptors sub-types, critical to memory consolidation. Pre-clinical testing has shown drastic reductions in fear, anxiety and depression, as well as the restoration of cognitive function. Finally, reduced neuroinflammation in neurodegenerative models paves the way for an extended development portfolio focusing on restoring the quality of lives of those affected by these debilitating diseases.